Skip to main navigation

News
Careers
Contact

About
Science
Pipeline
Patients
Investors
Menu Menu

Press Releases

Press Releases
Events & Presentations
- Events
- Presentations
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly Results
Stock Information
IR Resources

Year

eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

05.31.2023
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

05.26.2023
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

05.25.2023
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

05.09.2023
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

05.08.2023
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

04.26.2023
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

04.11.2023
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

03.28.2023
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

03.08.2023
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

02.21.2023

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Home
About
Science
Pipeline
Patients
Investors
News
Careers
Contact

Copyright © 2023 eFFECTOR Therapeutics, Inc. | Privacy Policy

Scroll to top